Member Directory

affinity bio

Website: http://www.affinitybio.com.au/

Member Contact: Ben Kiefel

Position: Chief Operating Officer

Industry: Biotech & Pharmaceuticals

Company Profile:

affinity bio was established in 2009 to develop an industry-beating, ultra-rapid antibody display platform, and has labs in the Small Technologies Cluster in Scoresby, Victoria.

Retained Display (ReD) is our proprietary, ultra-rapid antibody display platform. ReD delivers highly-soluble single chain antibodies from our diverse library within 5 days. The system generates sequence diverse, first-round antibodies of nanomolar affinities against antigens ranging from small peptides through to large proteins. Our highly-soluble scaffold is primed during the screening process for high-level expression in bacterial systems and ReD output is suitable for rapid conversion into Fab and bi-specific formats.

ReD is adaptable for other protein evolution projects including non-antibody scaffolds, enzymes, peptides and industrial proteins.

affinity bio is the recipient of grants under the Commercialisation Australia program which is currently supporting exemplification of ReD against collaborative targets.

Home

News & opinion

Member Directory

Events